checkAd
Verastem Aktie
2,760
 
USD
18.09.21 Nasdaq
+2,22 %
+0,060 USD
Geldkurs 17.09.21
2,760 USD
4.700 Stk.
Briefkurs 17.09.21
2,770 USD
114.500 Stk.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences: H.C. Wainwright …

Wertpapier:

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ended June 30, 2021 and highlighted recent progress. “There were …

Wertpapier:

Nachrichten

DatumTitel
27.07.21Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021
Business Wire (engl.) | Weitere Nachrichten
19.07.21Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt
Business Wire (engl.) | Weitere Nachrichten
06.07.21Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (engl.) | Weitere Nachrichten
24.06.21Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors
Business Wire (engl.) | Weitere Nachrichten
25.05.21Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference
Business Wire (engl.) | Weitere Nachrichten
24.05.21Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Business Wire (engl.) | Weitere Nachrichten
11.05.21Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Business Wire (engl.) | Weitere Nachrichten
18.03.21Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022
Business Wire (engl.) | Weitere Nachrichten
02.03.21Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference
Business Wire (engl.) | Weitere Nachrichten
20.01.21Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology
Business Wire (engl.) | Weitere Nachrichten
07.01.21Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (engl.) | Weitere Nachrichten
06.01.21Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Business Wire (engl.) | Weitere Nachrichten
05.01.21Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference
Business Wire (engl.) | Weitere Nachrichten
15.12.20Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer
Business Wire (engl.) | Weitere Nachrichten
30.11.20Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Business Wire (engl.) | Weitere Nachrichten